Literature DB >> 8265683

Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC.

B R Martin1, D R Compton, S F Semus, S Lin, G Marciniak, J Grzybowska, A Charalambous, A Makriyannis.   

Abstract

One aspect of cannabinoid structure-activity relationships (SARs) that has not been thoroughly investigated is the aromatic (A) ring. Although halogenation of the side chain enhances potency, our recent observation that iodination of the A ring also enhanced activity was surprising. The purpose of this investigation was to establish the steric and electrostatic requirements at these sites of the cannabinoid molecule via molecular modeling, while determining pharmacological activity. Molecular modeling was performed using the Tripos molecular mechanics force field and the semiempirical quantum mechanical package AM1. The Ki values for novel cannabinoids were determined in a [3H]CP-55,940 binding assay and ED50 values generated from four different evaluations in a mouse model. The present studies underscore the increase in potency produced by a dimethylheptyl (DMH) side chain. Trifluoro substitutions on the pentyl side chain, or bromination of the DMH side chain, had little effect on the pharmacological activity. Any substitution at the C4 position of the aryl ring resulted in a loss of activity, which appears to be due to steric hindrances. Nitro, but not iodo, substitution at the C2 position essentially produces an inactive analog, and the drastic alteration of the electrostatic potential appears to be responsible. The altered pharmacological profile of the 2-iodo analog seems to be related to an alteration in the highest occupied molecular orbital because there is no alteration in the electron density map compared to delta 8-tetrahydrocannibinol.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8265683     DOI: 10.1016/0091-3057(93)90356-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids.

Authors:  Peter J Crocker; Anu Mahadevan; Jenny L Wiley; Billy R Martin; Raj K Razdan
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

2.  Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.

Authors:  Jenny L Wiley; Valerie J Smith; Jianhong Chen; Billy R Martin; John W Huffman
Journal:  Bioorg Med Chem       Date:  2012-01-30       Impact factor: 3.641

3.  The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model.

Authors:  Spyros P Nikas; Jolanta Grzybowska; Demetris P Papahatjis; Avgui Charalambous; Ali R Banijamali; Ravi Chari; Pusheng Fan; Therapia Kourouli; Sonyuan Lin; Albert J Nitowski; Gilbert Marciniak; Yan Guo; Xiuyan Li; Chia-Lin J Wang; Alexandros Makriyannis
Journal:  AAPS J       Date:  2004-10-19       Impact factor: 4.009

4.  1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.

Authors:  Jenny L Wiley; Julie A Marusich; Billy R Martin; John W Huffman
Journal:  Drug Alcohol Depend       Date:  2011-11-27       Impact factor: 4.492

Review 5.  Covalent cannabinoid receptor ligands - structural insight and selectivity challenges.

Authors:  Ian Liddle; Michelle Glass; Joel D A Tyndall; Andrea J Vernall
Journal:  RSC Med Chem       Date:  2022-04-04

6.  Novel, potent THC/anandamide (hybrid) analogs.

Authors:  Caryl Bourne; Sucharita Roy; Jenny L Wiley; Billy R Martin; Brian F Thomas; Anu Mahadevan; Raj K Razdan
Journal:  Bioorg Med Chem       Date:  2007-08-25       Impact factor: 3.641

7.  Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.

Authors:  Teodora Georgieva; Savitha Devanathan; Dagmar Stropova; Chad K Park; Zdzislaw Salamon; Gordon Tollin; Victor J Hruby; William R Roeske; Henry I Yamamura; Eva Varga
Journal:  Eur J Pharmacol       Date:  2007-11-28       Impact factor: 4.432

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.